, WHO. World Health Organisation, 2018.
Multiple recurrences of major depressive disorder, Am J Psychiatry, vol.157, issue.2, pp.229-233, 2000. ,
The epidemiology of depression across cultures, Annu Rev Public Health, vol.34, pp.119-138, 2013. ,
Cross-national epidemiology of major depression and bipolar disorder, JAMA, vol.276, issue.4, pp.293-299, 1996. ,
Gender differences in depression in 23 European countries. Cross-national variation in the gender gap in depression, Soc Sci Med, vol.71, pp.305-313, 2010. ,
Major depression, Med Clin North Am, vol.98, issue.5, pp.981-1005, 2014. ,
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development, Nat Rev Drug Discov, vol.9, issue.8, p.628, 2010. ,
Mode of action of agomelatine: synergy between melatonergic and 5-HT2C receptors, World J Biol Psychiatry, vol.12, issue.8, pp.574-587, 2011. ,
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, Lancet, vol.391, pp.1357-1366, 2018. ,
Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies, Br Med J, vol.348, p.1888, 2014. ,
Placebo response and antidepressant clinical trial outcome, J Nerv Ment Dis, vol.191, issue.4, pp.211-218, 2003. ,
Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis, J Clin Psychiatry, vol.73, issue.10, pp.1300-1306, 2012. ,
A rating scale for depression, J Neurol Neurosurg Psychiatry, vol.23, issue.1, pp.56-62, 1960. ,
The responsiveness of the Hamilton depression rating scale, J Psychiatr Res, vol.34, issue.1, pp.3-10, 2000. ,
The Hamilton Depression Rating Scale: has the gold standard become a lead weight?, Am J Psychiatry, vol.161, issue.12, pp.2163-2177, 2004. ,
The use of rating scales exemplified by a comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale, Acta Psychiatr Scand, vol.62, issue.S285, pp.128-132, 1980. ,
Exactly what does the Hamilton depression rating scale measure?, J Psychiatr Res, vol.27, issue.3, pp.259-273, 1993. ,
A new depression scale designed to be sensitive to change, Br J Psychiatry, vol.134, issue.4, pp.382-389, 1979. ,
Improving the assessment of severity of depressive states: a reduction of the Hamilton Depression Scale, Pharmacopsychiatry, vol.18, issue.01, pp.114-115, 1985. ,
Assessing full remission, J Psychiatry Neurosci, vol.27, issue.4, p.235, 2002. ,
Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling, Pharm Res, vol.31, issue.8, pp.2152-2165, 2014. ,
Item response theory as an efficient tool to describe a heterogeneous clinical rating scale in de novo idiopathic Parkinson's disease patients, Pharm Res, vol.34, issue.10, pp.2109-2118, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01563224
A brief history of item theory response, J Educ Meas, vol.16, issue.4, pp.21-33, 1997. ,
New scoring methodology improves the sensitivity of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials, Alzheimer's Res Ther, vol.7, issue.1, p.64, 2015. ,
Differences in Alzheimer disease clinical trial outcomes based on age of the participants, Neurology, vol.84, issue.11, pp.1121-1127, 2015. ,
An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog), Psychol Assess, vol.28, issue.12, p.1576, 2016. ,
Application of item response theory to modeling of expanded disability status scale in multiple sclerosis, AAPS J, vol.19, issue.1, pp.172-179, 2017. ,
A longitudinal item response theory model to characterize cognition over time in elderly subjects, CPT Pharmacometrics Syst Pharmacol, vol.6, issue.9, pp.635-641, 2017. ,
Morphine Pharmacodynamics in Mechanically Ventilated Preterm Neonates Undergoing Endotracheal Suctioning, CPT Pharmacometrics Syst Pharmacol, vol.6, issue.4, pp.239-248, 2017. ,
Modeling a Composite Score in Parkinson's Disease Using Item Response Theory, AAPS J, vol.19, issue.3, pp.837-845, 2017. ,
Item response theory to quantify longitudinal placebo and paliperidone effects on PANSS scores in schizophrenia, CPT Pharmacometrics Syst Pharmacol, vol.6, issue.8, pp.543-551, 2017. ,
Model-based assessment of the benefits and risks of recombinant tissue plasminogen activator treatment in acute ischaemic stroke, Br J Clin Pharmacol, vol.84, issue.11, pp.2586-2599, 2018. ,
An item response theory based integrated model of headache, nausea, photophobia, and phonophobia in migraine patients, J Pharmacokinet Pharmacodyn, vol.45, issue.5, pp.721-731, 2018. ,
The basics of item response theory. ERIC, 2001. ,
Modelling placebo response in depression trials using a longitudinal model with informative dropout, Eur J Pharm Sci, vol.36, issue.1, pp.4-10, 2009. ,
Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial, J Clin Psychiatry, vol.70, issue.8, pp.1128-1137, 2009. ,
A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression, J Clin Psychopharmacol, 1993. ,
Nocebo in clinical trials for depression: a meta-analysis, Psychiatry Res, vol.215, issue.1, pp.82-86, 2014. ,
Statistical Analysis of Longitudinal Psychiatric Data with Dropouts, J Psychiatr Res, vol.41, issue.12, pp.1032-1041, 2007. ,
Modeling the drop-out mechanism in repeated-measures studies, J Am Stat Assoc, vol.90, issue.431, pp.1112-1121, 1995. ,
A joint model for nonlinear longitudinal data with informative dropout, J Pharmacokinet Pharmacodyn, vol.30, issue.1, pp.83-103, 2003. ,
Performance of nonlinear mixed effects models in the presence of informative dropout, AAPS J, vol.17, issue.1, pp.245-255, 2015. ,
Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder, Int J Neuropsychopharmacol, vol.10, issue.5, pp.661-673, 2007. ,
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder, Eur Neuropsychopharmacol, vol.16, issue.2, pp.93-100, 2006. ,
A placebocontrolled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder, Eur Neuropsychopharmacol, vol.24, issue.4, pp.553-563, 2014. ,
The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study, J Clin Psychiatry, vol.74, issue.6, pp.587-94, 2013. ,
Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model, J Pharmacokinet Pharmacodyn, vol.34, issue.1, pp.57-85, 2007. ,
Statistical power analysis for the behavioral sciences 2nd edn, Erlbaum Associates, 1988. ,
Comparison of proportional and differential odds models for mixed-effects analysis of categorical data, J Pharmacokinet Pharmacodyn, vol.35, issue.5, p.483, 2008. ,
Modeling composite assessment data using item response theory, CPT Pharmacometrics Syst Pharmacol, vol.7, issue.4, pp.205-218, 2018. ,
Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials, Br J Clin Pharmacol, vol.63, issue.5, pp.595-613, 2007. ,
Population disease progress models for the time course of HAMD score in depressed patients receiving placebo in anti-depressant clinical trials. Abstracts of the XI annual meeting of the population approach group in Europe, 2002. ,
Pharmacometrics: the science of quantitative pharmacology, pp.547-581, 2007. ,
Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder, J Pharmacokinet Pharmacodyn, vol.36, issue.1, pp.63-80, 2009. ,
, NONMEM users guide: Introduction to NONMEM 7.3.0, 2013.
Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression, Clin Pharmacol Ther, vol.91, issue.5, pp.863-871, 2012. ,
Effect of Agomelatine in the Chronic Mild Stress Model of Depression in the Rat, Neuropsychopharmacology, vol.28, issue.4, p.694, 2003. ,
Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal, Int J Neuropsychopharmacol, vol.15, issue.3, pp.417-428, 2012. ,
Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials, Br J Psychiatry, vol.203, issue.3, pp.179-187, 2013. ,
Handbook of clinical rating scales and assessment in psychiatry and mental health, pp.7-35, 2009. ,
Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine, Proc Natl Acad Sci, vol.89, issue.23, pp.11466-11470, 1992. ,
Severity classification on the Hamilton depression rating scale, J Affect Disord, vol.150, issue.2, pp.384-388, 2013. ,
R: A Language and Environment for Statistical Computing, 2018. ,
Simulation of Longitudinal Data, 2018. ,